NCT03365479 is a NA clinical trial of Iloprost in Pulmonary Hypertension, sponsored by University of Giessen.

Who is sponsoring NCT03365479?

NCT03365479 is sponsored by University of Giessen.

What drugs are being tested in NCT03365479?

Interventions in NCT03365479: Iloprost.

What condition does NCT03365479 study?

NCT03365479 studies Pulmonary Hypertension, Pulmonary Arterial Hypertension.

Is NCT03365479 still recruiting?

NCT03365479 is currently completed. Last updated 26 October 2018.

Last reviewed 2018-10-26 · How we verify

NCT03365479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension

Completed NA Last updated 26 October 2018

What this trial tests

NA trial testing Iloprost in Pulmonary Hypertension in 30 participants. Completed in 24 October 2018.

Timeline

1 May 2017

Primary endpoint
1 August 2018

24 October 2018

Quick facts

Lead sponsor	University of Giessen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	30
Start date	1 May 2017
Primary completion	1 August 2018
Estimated completion	24 October 2018
Sites	2 locations across Germany

Drugs / interventions tested

Iloprost — full drug profile →

Conditions studied

Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →

Sponsor

University of Giessen

Who can join

18 and older, any sex, with Pulmonary Hypertension or Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary objective • To evaluate the effect of rapid inhalation of 2.5μgiloprost using the Breelib nebulizer on pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension Secondary objectives * To evaluate the effect of rapid iloprost inhalation using the Breelib nebulizer on mean pulmonary arterial pressure (mPAP), cardiac output (CO), cardiac index (CI), systemic blood pressure, arterial oxygen saturation, heart rate, and pulmonary arterial wedge pressure (PAWP). * To evaluate the safety and tolerability of the rapid iloprost inhalation using the Breelib nebulizer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study.
Richter MJ, Wan J, Ghofrani HA, Seeger W, et al · · 2019 · cited 4× · PMID 31588353 · DOI 10.1177/2045894019875342

Verify or expand the search:

Other trials of Iloprost

Trials testing the same drug.

NCT05411107 — Oral Iloprost for the Prevention of Lung Cancer In Former Smokers · Phase 2 · withdrawn
NCT06319274 — Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure · Phase 2 · recruiting
NCT04420741 — Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure · Phase 2 · completed
NCT04123444 — Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure · Phase 2, PHASE3 · completed
NCT03111212 — Iloprost in Acute Respiratory Distress Syndrome · Phase 3 · completed

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting

Other University of Giessen trials

Trials by the same sponsor.

NCT07505511 — Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in · EARLY_PHASE1 · not yet recruiting
NCT07488468 — Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures · recruiting
NCT06966739 — Multispectral Optoacustic Imaging in Patients With Myositis · completed
NCT06381427 — Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure · NA · recruiting
NCT06291714 — Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03365479 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Giessen
Last refreshed: 26 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03365479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing